ArticleDiscover oncology2026

Long term survival with trastuzumab deruxtecan for heavily pretreated, HER2 mutated advanced non-small cell lung cancer.

Ping Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.